Giustina, A. http://orcid.org/0000-0001-6783-3398
Uygur, M. M. http://orcid.org/0000-0002-6569-8142
Frara, S. http://orcid.org/0000-0002-1308-5598
Barkan, A. http://orcid.org/0000-0002-5453-0248
Biermasz, N. R. http://orcid.org/0000-0001-5817-3594
Chanson, P. http://orcid.org/0000-0001-5096-5722
Freda, P. http://orcid.org/0000-0002-1818-0762
Gadelha, M. http://orcid.org/0000-0002-9250-3558
Kaiser, U. B.
Lamberts, S.
Laws, E.
Nachtigall, L. B.
Popovic, V.
Reincke, M. http://orcid.org/0000-0002-9817-9875
Strasburger, C.
van der Lely, A. J. http://orcid.org/0000-0002-1059-0126
Wass, J. A. H.
Melmed, S. http://orcid.org/0000-0002-2355-3447
Casanueva, F. F. http://orcid.org/0000-0002-9052-8161
Funding for this research was provided by:
Pfizer (54333635, 54333635, 54333635, 54333635)
Article History
Accepted: 24 July 2023
First Online: 28 August 2023
Declarations
:
: A. Giustina is Consultant for Ipsen, Pfizer, Recordati and Takeda and received Research Grants to Institutions from Abiogen, Pfizer and Takeda. M.M. Uygur received a Grant from Pfizer. S. Frara received consultancy and speaker fees from Ipsen, Pfizer, Novartis and Recordati. A.J. van der Lely received consultancy and/or speakers’ fees from Amoly Pharma SA, Dexel, Cambian, Crinetics, Ipsen and Pfizer. S. Melmed is a Consultant for Ionis, Ipsen and NovoNordisk and receives a Research Grant from Recordati. A. Barkan, F.F. Casanueva, P. Chanson, P. Freda, M. Gadelha, S. Lamberts, U.B. Kaiser, L.B. Nachtigall, V. Popovic, M. Reincke, C. Strasburger, J.A.H. Wass have no conflicts of interest.
: Ethical approval is not required for this study.